Knightscope, Soligenix, and Genetic Technologies Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / October 6, 2023 / RedChip Companies will air interviews with Knightscope, Inc. (NASDAQ:KSCP), Soligenix, Inc. (Nasdaq:SNGX), and Genetic Technologies Limited (ASX:GTG)(NASDAQ:GENE) on The RedChip Small Stocks Big Money …
ORLANDO, FL / ACCESSWIRE / October 6, 2023 / RedChip Companies will air interviews with Knightscope, Inc. (NASDAQ:KSCP), Soligenix, Inc. (Nasdaq:SNGX), and Genetic Technologies Limited (ASX:GTG)(NASDAQ:GENE) on The RedChip Small Stocks Big Money Show, a sponsored program on Bloomberg TV, this Saturday, October 7, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Access the interviews in their entirety at:
- Knightscope: https://www.redchip.com/assets/access/knightscope_access.html
- Soligenix: https://www.redchip.com/assets/access/sngx_access
- Genetic Technologies: https://www.redchip.com/assets/access/gene_access
William Santana Li, CEO and Chairman of Knightscope, Inc., appears on the RedChip Small Stocks Big Money Show on Bloomberg TV to provide a corporate update. Knightscope is an advanced security technology company based in Silicon Valley that builds fully autonomous security robots that deter, detect, and report. The Company's groundbreaking technology has proven to help in fighting crime and providing security and public safety professionals unprecedented situational awareness. Knightscope's cost-effective security robots help secure the places you live, work, study and visit. The Company's long-term ambition is to make the United States of America the safest country in the world.
Lesen Sie auch
Also appearing on the RedChip Small Stocks Big Money Show this week is Dr. Chris Schaber, CEO of Soligenix. Soligenix, a late-stage biopharmaceutical company, offers a robust pipeline of multiple fast-track and orphan-designated products with the potential for significant commercial returns of approximately $2 billion in global annual sales. Soligenix's late-stage clinical assets include HyBryte (SGX301), a photodynamic therapy for the treatment of cutaneous T-cell lymphoma (CTCL). The positive statistically significant results achieved in the Phase 3 study of HyBryte have been published in JAMA Dermatology, and the Company is preparing to meet with the FDA to discuss the design of the second confirmatory Phase 3 study. The estimated global market potential for HyBryte is $250 million, making it a significant commercial opportunity in an area of unmet medical need.